Inclusion Criteria:

• Must Be Over 20 Years Of Age, Regardless Of Sex
• Must Have A Diagnosis Of OA That Requiring Treatment
• Patients Must Have Taken an NSAID, Cox-2 Or Opioids On The Majority Of Days During The Last 4 Weeks Before Enrollment Who Are Intolerant (Due To Gastrointestinal Adverse Events) Or Inadequately Respond To Current Therapy (Vas D 40mm On A Pain Scale From 0-100mm)
• Excepting Osteoarthritis, The Patient Is Judged To Be In Otherwise General Good Health Based On Medical History, Physical Examination, And Routine Laboratory Tests
• Must Agree To Participate Voluntarily In The Study
• Must Have The Capacity To Understand And Answer The Questionnaires Used In The Study
• Must Agree To Return For A Follow-Up Visit With The Treating Physician Four Weeks After The Initiation Of Treatment With Etoricoxib
• Patient Is Willing To Sign Informed Consent Form

Exclusion Criteria:

• Under 20 Years Of Age
• Severe Hepatic Insufficiency (Child-Pugh Score > 9)
• Advanced Renal Insufficiency (Creatinine Clearance < 30 Ml/Min)
• Any Contraindication Or Warning Or Precaution As Mentioned In The Approved Study Drug Package Insert
• Gi Ulcer With Active Bleeding Present At Study Enrollment
• Patient Has A Recent History Of Stroke, Myocardial Infarction Or Transient Ischemic Attack (Within The Previous 2 Years)